Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
FTSE 250-listed company Hikma Pharmaceuticals has announced that following the conclusion of its strategic review of its global Injectables business, it has decided that the business should remain part of the Hikma Group. The reason behind the decision is that it sees the business as holding a uni
Read moreAfrican Barrick Gold: Deutsche Bank cuts target price from 230p to 173p, while its hold recommendation is reiterated. Ashmore Group: Morgan Stanley raises target price from 395p to 444p and maintains an equal-weight rating. Ashtead Group: Jefferies increases target price from 615p to 690o and reit
Read more
LONDON, April 15 (Reuters) - The following FTSE 100 companies will go ex-dividend on Wednesday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by marke
Read moreAmara Mining: After having been under review, Cantor Fitzgerald reinitiates coverage with a price target of 81p and a buy recommendation. Antofagasta: Citigroup shifts target price from 990p to 1000p, but retains its sell recommendation. Ashtead Group: Investec raises target price from 475p to 700
Read moreTraders chose to take profits on Wednesday morning, taking advantage of the strong gains seen in previous sessions, with the FTSE 100 pulling back sharply from five-year highs. So far this year, the index has gained nearly 10% and is trading near levels not seen since late 2007. According to Reute
Read morePharmaceuticals group Hikma registered an impressive increase in revenue in 2012, helped by strong performances from both the Branded and Injectables divisions, but warned that sales growth would slow this year. After the 20.8% growth seen in 2012, the company said that the rate would reduce to ar
Read moreAggreko: JP Morgan takes target price from 1845p to 1870p, while reiterating a neutral rating. Anglo American: Nomura reduces target price from 1800p to 1700p and downgrades from neutral to reduce. ARM Holdings: Deutsche Bank increases target price from 400p to 445p, but still recommends selling.
Read moreFor a third day in a row, the FTSE 100 index rallied in afternoon trade on the back of strong economic figures from America, as investors temporarily shrugged off concerns about the automatic spending cuts which kick in later today. US President Barack Obama met with congressional leaders this afte
Read moreHikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future, prompting a strong rise in the share price. High Street betting shop William Hill jumped after announcing th
Read moreHikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future. In a statment the group's Chief Executive Officer said: "We have received a number of unsolicited expression
Read moreAZ Electronic Materials: Goldman Sachs moves target price from 440p to 450p and retains a buy recommendation. Bovis Homes Group: Deutsche Bank shifts target price from 667p to 679p, while downgrading to hold. British American Tabacco: Investec places its target price (previously 3350p) and buy rec
Read moreAfrican Barrick Gold: Deutsche Bank cuts target price from 410p to 340p, while staying with its hold recommendation. Investec reduces target price from 405p to 315p and downgrades from buy to hold. JP Morgan lowers target price from 370p to 290p and downgrades to underweight. AG Barr: Barclays down
Read moreFTSE 250-listed pharmaceuticals group Hikma Pharmaceuticals has signed an agreement with EffRx for the licensing and distribution of osteoporosis treatment Binosto. The treatment, which is to be distributed throughout the Middle East and North Africa (MENA), represents the only buffered solution f
Read moreAfrican Barrick Gold: Investec lowers its target price from 526p to 405p, while upgrading from hold to buy. ARM Holdings: Morgan Stanley raises its target price from 725p to 911p, while downgrading to equal-weight. Investec ups target price from 800p to 900p and downgrades from buy to hold. Aurum
Read moreSainsbury's update yesterday revealed that Christmas same-store sales rose at the lowest rate seen in eight years. However, Questor thinks there was a lot to be optimistic about in the announcement. The company's like-for-like sales met expectations and its higher-margin (but cheaper) own-label good
Read more
Last checked at